Neovacs, a biotechnology company focused on active immunotherapy for autoimmune and inflammatory diseases and cancer, announced the final results of its Phase 1/2 clinical trial of TNF-Kinoid which showed:
• the drug candidate’s excellent safety profile in all subjects
• an immune response to the drug as intended
• a high clinical response rate, with clinical remission (absence of symptoms) in almost half the patients
The TNF-K-001 Phase I/IIa clinical trial was performed in 21 patients suffering from moderate to severe Crohn’s disease (defined as a Crohn’s Disease Activity Index (CDAI) of between 220(1) and 400). Each patient received three administrations of one of three dose levels of TNF-Kinoid (60 mcg, 180 mcg or 360 mcg) on days 0, 7 and 28, with four patients also receiving a maintenance dose at month 6. The study’s primary objective was to assess TNF-Kinoid’s safety and its ability to induce an immune response to tumor necrosis factor (TNF). The final results presented today confirm the drug candidate’s excellent safety profile; no treatment-related serious adverse events, unusual infections or premature study withdrawals were recorded. Reactions to administration of the Kinoid (whether local or systemic) were mild, transient and limited to a few patients.
In terms of immune response, in 17 of the 21 treated patients, TNF-Kinoid induced the production of anti-TNF antibodies. Of the three patients receiving the lowest dose (60 mcg), only one mounted an immune response to TNF. In both the 180 and 360 mcg dose levels, 8 of the 9 patients in each group (89%) produced anti-TNF antibodies.
In terms of clinical response (at study week 12 and after 3 administrations of the drug), 76% of the patients showed a significant clinical improvement (defined as a 70-point drop in the CDAI) and 43% of these patients were in clinical remission (i.e. the absence of symptoms, as evidenced by a CDAI at or below 150).
“These results are highly encouraging and promising. They constitute a key milestone for Neovacs and mark the start of our validation of this unique therapeutic approach based on active anti-cytokine immunization”, commented Neovacs CEO Guy-Charles Fanneau de La Horie. “The study enabled us to gather extensive data on TNF-Kinoid’s safety and immunogenicity. Our ongoing clinical development program is designed to confirm these results in the months ahead, as announced at the time of our IPO: we are in the process of initiating a double-blind, placebo-controlled Phase II study in Crohn’s disease”, he added.
“Despite progress in treating Crohn’s Disease, both patients and doctors want to see new treatments,” noted Professor Antoine Cortot, Head of the Gastroenterology Department at Lille Hospital- France. “These first results with the TNF-Kinoid in 21 Crohn’s patients are promising; they now need to be confirmed in a larger number of patients”
Date: December 8, 2010
Source: Neovacs S.A.
Filed Under: Drug Discovery
